Artax Biopharma's AX-158, a first-in-class oral Nck modulator, has achieved clinical validation in a Phase 2a trial for psoriasis, showcasing a novel approach to autoimmune disease treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.